Discovery of a Novel p38α-MK2 Complex Inhibitor as a Potential Choice for Autoimmune Diseases
Journal of Medicinal Chemistry · 2025
DOI: 10.1021/acs.jmedchem.4c01925 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2025. Verfasst von Donglin Fu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Chemical Pharmaceutical Research Center, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai 200120, P.R. China. Hauptthemen laut MEDLINE: Rats, Inbred Lew, Arthritis, Experimental, Mitogen-Activated Protein Kinase 14, Protein Serine-Threonine Kinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 26 Literaturangaben. Gefördert von: GeneScience Pharmaceutical Co., Ltd..
Abstract (Originalsprache)
The p38α-MK2 signaling axis plays an important role in the inflammatory response of cells. Here, we carried out a series of optimizations on CDD-450, aiming to enhance inhibition of the p38α-MK2 complex and improve pharmacokinetic properties. First, the magic F strategy was utilized to obtain compound 21, which displayed a 60-fold increase in tumor necrosis factor α inhibition and a 600-fold increase in interleukin-6 inhibition. Molecular dynamics simulations revealed insights into the binding mode of fluorinated molecules. Subsequently, introducing a methyl group and a fluorine group led to compound 36, which showed improved pharmacokinetic properties in rats and dogs. Evaluation in the Lewis rat adjuvant-induced arthritis model showed that compound 36 had a robust inflammation inhibitory effect and joint repair ability. Currently, compound 36 is being considered for preclinical development as a potential treatment for inflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Chemical Pharmaceutical Research Center, Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai 200120, P.R. China.
- Changchun GeneScience Pharmaceutical Co., Ltd., Shanghai 200120, P.R. China.
ORCID-Profile: Zimo Yang, Zhilong Hu
Förderung
- GeneScience Pharmaceutical Co., Ltd.
Zitieren
APA
Fu, D., Yang, Z., Jia, X., Han, T., Han, L., Zhang, X., Xia, Y., Wang, S., Jin, L., Hu, Z., & Yang, F. (2025). Discovery of a Novel p38α-MK2 Complex Inhibitor as a Potential Choice for Autoimmune Diseases. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.4c01925
Vancouver
Fu D, Yang Z, Jia X, Han T, Han L, Zhang X, et al. Discovery of a Novel p38α-MK2 Complex Inhibitor as a Potential Choice for Autoimmune Diseases. Journal of Medicinal Chemistry. 2025. doi:10.1021/acs.jmedchem.4c01925
BibTeX
@article{Fu2025,
author = {Fu, Donglin and Yang, Zimo and Jia, Xiangyu and Han, Tian and Han, Long and Zhang, Xiaobing and Xia, Yuanfeng and Wang, Siqin and Jin, Lei and Hu, Zhilong and Yang, Fanglong},
title = {Discovery of a Novel p38α-MK2 Complex Inhibitor as a Potential Choice for Autoimmune Diseases},
journal = {Journal of Medicinal Chemistry},
year = {2025},
doi = {10.1021/acs.jmedchem.4c01925}
}
EUVIMED